Phage therapy uses viruses that infect and kill specific bacteria. It's getting new attention as antibiotic resistance spreads, but the evidence is still thin.
What the trial evidence says:
A 2024 systematic review in Medical Principles and Practice searched PubMed for randomized controlled trials of phage therapy. It found only 7 eligible RCTs with 418 participants in total, covering indications like bacterial diarrhea, urinary tract infections, infected burn wounds, chronic otitis, leg ulcers, and chronic rhinosinusitis. Three of the studies reported a statistically significant difference versus standard of care or placebo. The authors say the trials suggest safety, but limitations in study design are why phage therapy isn't widely accepted yet. Publications on the topic increased more than fourfold, from 212 articles in 2011 to 739 in 2022.
Case series are more encouraging, but weaker evidence:
A UC San Diego and Pittsburgh team treated 20 patients with complex, antibiotic-refractory mycobacterial lung infections. There were no adverse reactions, and more than half had favorable clinical outcomes. Case series like this have no control group, so they can't show that the phage caused the improvement.
What's next:
A Phase 1 multi-center pilot trial (NCT07280598) is testing IV phage therapy combined with standard IV antibiotics in adults with cystic fibrosis who have antibiotic-resistant lung infections. Its primary endpoint is safety and tolerability, and it's expected to finish in December 2026.
Questions for discussion:
Phages are highly specific. Is that mostly a strength (targeting) or a weakness (matching each patient's strain)?
What trial design would convince regulators: non-inferiority against antibiotics or add-on trials?
How should phage manufacturing and regulation handle products that may need updating as bacteria evolve?